This blend is studied in receptor models involving GHRH and growth-hormone secretagogue signaling, ligand interaction, and pathway crosstalk.
- GHRH receptor signaling
- GHSR receptor signaling
- Receptor-pathway crosstalk
One vial, two secretagogue sequences
This blend is the CJC-1295 (No DAC) plus Ipamorelin listing. Papers on it sit at GHRH receptor signaling and GHSR receptor signaling. It is not the Ipamorelin-only vial.
Task 121834, batch CP-10, March 17, 2026, prints CJC-1295 (mod GRF 1-29) 7.27 mg and Ipamorelin 5.97 mg. No purity row.
The labeled total is 10 mg
The label is 5 mg plus 5 mg, $49.99. The report lists two masses. Do not collapse them into one purity percent.
This page is laboratory education for adults 21 and older. It is not a dosing guide, a treatment plan, or a ranking of which material to use. Not for human or veterinary use.
CJC-1295 (No DAC) 5 mg + Ipamorelin 5 mg research questions
What does task 121834 print?
CJC-1295 (mod GRF 1-29) 7.27 mg and Ipamorelin 5.97 mg. No purity percent.
Is Ipamorelin alone the same product?
No. Ipamorelin 10 mg is $39.99, task 150447.
References and further reading
- PubMed literature index — CJC-1295 (No DAC) 5 mg + Ipamorelin 5 mg ↗
A continuously updated index of peer-reviewed biomedical literature. Study quality, model, and relevance must be assessed individually.
- FDA — Analytical Procedures and Methods Validation ↗
Regulatory guidance on analytical method development and validation.
- ICH Q2(R2) — Validation of Analytical Procedures ↗
International guidance on specificity, accuracy, precision, range, and robustness.
- Hoofnagle et al. — Recommendations for peptide storage and handling ↗
Peer-reviewed recommendations for peptide handling in quantitative laboratory workflows.
External links are provided for independent literature review. A link does not imply that every indexed paper supports the same conclusion or that findings apply beyond the model and conditions studied.
